Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces dose-dependent reductions in HbA1c (up to 2.4%) and body weight (up to 11.3 kg) in patients with Type 2 Diabetes, with efficacy superior to the GLP-1 receptor agonist dulaglutide.
If you have Type 2 Diabetes, Tirzepatide is a once-weekly injection that significantly lowers blood sugar (HbA1c) and promotes substantial weight loss, outperforming existing GLP-1 drugs like dulaglutide in clinical trials. It works by mimicking two gut hormones (GIP and GLP-1) to improve insulin response and reduce appetite. While gastrointestinal side effects like nausea are common, they are usually mild and can be managed by starting with a low dose and increasing gradually. This treatment is suitable for adults with T2DM, including those already taking metformin.
In the phase 1 and phase 2 trials tirzepatide demonstrated dose-dependent reduction in HbA1c (up to 2.4%) and body weight (up to 11.3 kg) in patients with T2DM. The clinical efficacy of tirzepatide is superior to the GLP-1 RA dulaglutide.
Why this rating
Based on multiple randomized, placebo-controlled phase 1 and 2 clinical trials with clear statistical significance reported.
Source
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
Thinzar Min et al. · Diabetes Therapy · 2020
DOI 10.1007/s13300-020-00981-0
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →